Lebwohl, M.; Strober, B.; Linaberry, M.; Hoyt, K.; Banerjee, S.; Kisa, R. M.; Mehta, N. N. Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Evaluation of Lipid Parameters in the Phase 3 POETYK PSO-1 and PSO-2 Trials. J of Skin 2023, 7, s115.